Biocon Biologics

The government has granted the sanction to prosecute Central Drugs Standard Control Organisation's joint drugs controller S Eswara Reddy, clearing the decks for initiating a trial against him for allegedly taking a bribe to favourably recommend Biocon Biologics' insulin injection, officials said Sunday.

Shreehas Tambe takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the Biocon Biologics board, the company said

The CBI has filed a charge sheet against five persons, including a Joint Drug Controller of the Central Drugs Standard Control Organisation(CDSCO) and a Biocon Biologics executive, in a Rs nine lakh bribery case.

Biocon Biologics has denied allegations of bribery against the company and its officials regarding approval for one of its products in India

Biocon Ltd on Thursday reported a 4 per cent decline in consolidated net profit to Rs 283.9 crore in the fourth quarter ended on March 31, 2022

Biocon Biologics, a subsidiary of Biocon, will file for an initial public offer (IPO) within the next two years, Kiran Mazumdar-Shaw said on Monday.

Biocon Biologics, an arm of biotechnology major Biocon, on Thursday said clinical study for its biologic drug Itolizumab for possible indication in autoimmune disease Lupus Nephritis has been initiated in India after approval from the Drugs C

Biocon Biologics will offer approximately 15 per cent stake to SILS, at a valuation of $4.9 billion.

Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.

The licence will be effective until the COVID-19 outbreak is controlled in the country, the company said in a regulatory filing.

Biotechnology major Biocon on Thursday posted a 17 per cent rise in net profit at Rs 147 crore for the fiscal first quarter that ended on June 30, 2016, on the back of robust growth in segments like biologics and branded formulations.

This episode of Walk The Talk features Biocon chief Kiran Mazumar Shaw talking about the need to leverage India's strong biology base into innovation.

The company, which is pursuing R&D in both novel biologics as well as biosimilars (generic versions of biologic drugs), in various stages of trials, had spent around Rs 131 crore on R&D in the previous fiscal year which was 6 per cent of biopharma sales.

India's leading biotech firm Biocon has unveiled a new drug to treat psoriasis, a skin disease that occurs when the immune system mistakes a normal skin cell for a pathogen."Psoriasis is a socially debilitating disease affecting around three percent of...

Alzumab, now commercially available in the country for treating patients with chronic plaque psoriasis, was priced at least 50 per cent lower than similar drugs in the market, the company's chairperson and managing director, Kiran Mazumdar-Shaw told a news conference here.

The government has granted the sanction to prosecute Central Drugs Standard Control Organisation's joint drugs controller S Eswara Reddy, clearing the decks for initiating a trial against him for allegedly taking a bribe to favourably recommend Biocon Biologics' insulin injection, officials said Sunday.

Shreehas Tambe takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the Biocon Biologics board, the company said

The CBI has filed a charge sheet against five persons, including a Joint Drug Controller of the Central Drugs Standard Control Organisation(CDSCO) and a Biocon Biologics executive, in a Rs nine lakh bribery case.

Biocon Biologics has denied allegations of bribery against the company and its officials regarding approval for one of its products in India

Biocon Ltd on Thursday reported a 4 per cent decline in consolidated net profit to Rs 283.9 crore in the fourth quarter ended on March 31, 2022

Biocon Biologics, a subsidiary of Biocon, will file for an initial public offer (IPO) within the next two years, Kiran Mazumdar-Shaw said on Monday.

Biocon Biologics, an arm of biotechnology major Biocon, on Thursday said clinical study for its biologic drug Itolizumab for possible indication in autoimmune disease Lupus Nephritis has been initiated in India after approval from the Drugs C

Biocon Biologics will offer approximately 15 per cent stake to SILS, at a valuation of $4.9 billion.

Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.

The licence will be effective until the COVID-19 outbreak is controlled in the country, the company said in a regulatory filing.

Biotechnology major Biocon on Thursday posted a 17 per cent rise in net profit at Rs 147 crore for the fiscal first quarter that ended on June 30, 2016, on the back of robust growth in segments like biologics and branded formulations.

This episode of Walk The Talk features Biocon chief Kiran Mazumar Shaw talking about the need to leverage India's strong biology base into innovation.

The company, which is pursuing R&D in both novel biologics as well as biosimilars (generic versions of biologic drugs), in various stages of trials, had spent around Rs 131 crore on R&D in the previous fiscal year which was 6 per cent of biopharma sales.

India's leading biotech firm Biocon has unveiled a new drug to treat psoriasis, a skin disease that occurs when the immune system mistakes a normal skin cell for a pathogen."Psoriasis is a socially debilitating disease affecting around three percent of...

Alzumab, now commercially available in the country for treating patients with chronic plaque psoriasis, was priced at least 50 per cent lower than similar drugs in the market, the company's chairperson and managing director, Kiran Mazumdar-Shaw told a news conference here.